Third-Quarter 2025 Business Review

Marcy l’Étoile, France, November 4, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2025.
 

• 7.3% organic sales growth in the first nine months of the year, fully in line with annual guidance, with sales reaching a total of €2,992m, primarily driven by a 9% organic increase across the four growth drivers of the GO•28 strategic plan:
  • BIOFIRE^® non-respiratory panels recorded a 10% organic sales growth, driven by increase in all panels and a sustained installed base expansion;
  • SPOTFIRE^® continued its strong growth trajectory with 114% organic sales increase year on year. The pace of instrument installations accelerated in Q3, with over 900 new instruments, bringing the total installed base to more than 5,500 instruments at the end of September more than doubling over 12 months (+160%);
  • Microbiology organic sales growth reached 5% excluding China, while the overall performance (+3%) was impacted by a double-digit decline in China;
  • Industrial Applications: strong dynamic with a 10% organic sales increase, driven by 15% organic sales growth in the Pharma Quality Control segment leveraging on new products launches (molecular range, 3P^® ENTERPRISE);
• BIOFIRE^® respiratory panels sales rose by 6% organically, reflecting a strong epidemiological activity in Q1 and lower levels in Q2 and Q
• 3% organic sales growth in Q3 impacted by continuous mid-teens decrease in China and a 8% decline in BIOFIRE^® Respiratory Panels (low epidemiology). Excluding those two elements, Q3 performance stands at +7.6%.
• 2025 full year guidance:
  • Sales are now expected to grow between +5.5% and +6.5% at constant exchange rates (versus between +6% and +7.5% previously) on a late respiratory season.
  • Confirmation of the expected +12% to +18% growth in contributive operating income before non-recurring items (CEBIT) at constant exchange rates, based on a nine months profitability fully aligned with the GO•28 trajectory.
• The currency effect is expected to have a negative impact in the range of around - €30m on the 2025 annual CEBIT versus around -€25m previously.

Pierre Boulud, Chief Executive Officer, said: “In a context of low epidemiological activity, we continue to expand our installed base, particularly for BIOFIRE^® and SPOTFIRE^®, at a faster pace than in 2024, building a strong platform for growth for the coming years. At the same time, bioMérieux continues to deliver on its GO•28 ambition, with significant profitability improvement and sustained innovation through several product launches since the start of the year.”